OREANDA-NEWS. According to the results of the first quarter of 2013 total sales of the top five best selling Rx drugs amounted to RUR 359.65 million, which corresponds to 37.5% of sales in the Rx drugs segment and 31.7% of the Company’s total sales.

According to the results of the first quarter of 2013 the top five best selling Rx drugs are:

- Geptor (Ademetionine; ATC "Digestive tract and metabolism"); sales increased by 47.5% as compared to the same period of previous year; 15% of sales in the Rx drugs segment;

- Irunine (Itraconazole; ATC "Antimicrobials for systematic use"); sales in the segment made 6.4%;

- Cerepro (Choline Alfoscerate; ATC "Medications for the treatment of central nervous system deseases"); sales in the segment made 6.0%;

- Carboplatin-LENS (Carboplatin, ATC "Antineoplastic and immunomodulating agents"); sales in the segment made 5.2%;

- Doxorubicin-LENS (Doxorubicin, "Antineoplastic and immunomodulating agents"); sales in the segment made 4.9%.

OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 97.3% of sales.

- Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales increased by 41.3% as compared to the same period of the previous year; sales in the OTC drugs segment made 37.9%;

- Xilen (Xylometazoline; ATC "Medications for the treatment of respiratory system"); sales in the OTC drugs segment made 27.9%;

- Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales in the OTC drugs segment made 24.8%;

- Vitasharm and Vitatress (ATC "Vitamins"); sales in the OTC drugs segment made 5.2%;

- Ginecotex (Benzalkonium chloride; ATC "Medications for the treatment of urogenital organs"); sales in the OTC drugs segment made 1.5%.

Traditional drugs segment

According to the results of the first quarter of 2013 the top five best selling prescription medications are:

- Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs for systematic use"); sales in the traditional drugs segment made 42.5%;

- Vero-Ciprofloxacin (Ciprofloxacin; ATC "Antimicrobials for systematic use"); sales in the segment made 34.5%;

- Drotaverine (Drotaverine; (ATC "Alimentary tract and metabolism"); sales in the segment made 14.3%;

- Pyridoxine (ATC "Alimentary tract and metabolism"); sales in the segment made 7.2%;

- Vero-Loperamide (Loperamide; ATC "Alimentary tract and metabolism"); sales in the segment made 1.6%.

Non-pharamaceutical products

According to the results of the first quarter of 2013 the top five best selling non-pharamaceutical products are:

- Conventional reel adhesive bandages; 41.4% of sales in the segment;

- Conventional antimicrobial adhesive bandages; 15.8% of sales in the segment;

- Therapeutic patches - pepper plasters; 13.3% of sales in the segment;

- Therapeutic patches - corn plasters; 11.8% of sales in the segment;

- Condoms; 1.6% of sales in the segment.

NEW DRUGS PRODUCTION AND SALES

During the first quarter of 2013 Veropharm launched production and sales of the following new drugs and cosmetic products:

- Anfibra (Enoxaparin sodium; ATC "Medications affecting hematogenesis and blood");

NEW DRUGS REGISTRATION

In the first quarter of 2013 none drugs have been registered:

At present, 21 drugs are currently at different stages of the registration process.